Trial Profile
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Sep 2017
Price :
$35
*
At a glance
- Drugs Avibactam/ceftazidime (Primary) ; Avibactam
- Indications Gram-negative infections; Intra-abdominal infections; Urinary tract infections
- Focus Adverse reactions
- 16 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Feb 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 15 Feb 2011 New trial record